Former President Bill Clinton, keynote speaker at the Forum
NEW YORK, March 13 /CNW/ -- Former President Bill Clinton joined global
diabetes leaders today in New York City to discuss ways to break the curve of
the diabetes pandemic at a forum hosted by Novo Nordisk and supported by the
International Diabetes Federation (IDF).
At the first meeting of policymakers, patient organizations, healthcare
professionals, and media since the United Nations passed a resolution to
address diabetes in December 2006, the discussion explored ways to make
diabetes a global health priority and ultimately, improve the way the disease
Today, 20.8 million Americans -- or seven percent of the population --
have diabetes, at least 10 million of whom are not in control of the
condition. It is estimated that one in three American children born in 2000
and beyond will develop type 2 diabetes. Worldwide, an estimated 246 million
people have diabetes, a number that is expected to grow to 380 million within
the next 20 years if no urgent action is taken. Diabetes accounts for 3.8
million deaths per year globally, similar in magnitude to HIV/AIDS.
The Global Changing Diabetes Leadership Forum hopes to redefine
healthcare around the needs of people with diabetes.
"Recognizing that there is not a single answer to the diabetes pandemic,
Novo Nordisk hopes to provide a forum for identifying multiple actions at all
stages to combat diabetes -- from prevention to the treatment of serious
complications," said Lars Rebien Sorensen, president and CEO of Novo Nordisk.
"Only by placing the person with diabetes at the center of care and changing
how healthcare systems around the world approach the disease can this silent
killer be defeated."
Martin Silink, president of the IDF, emphasized that "the reality is that
there will not be an automatic increase in funds for diabetes for either
prevention or treatment in the short term. In developing countries, which bear
70% of the global burden of diabetes, the solutions will involve increasing
access to proven but low-cost therapies."
During the two day Forum, attendees from around the world will
participate in a series of workshops and dialogues designed to evoke a
provocative debate about how to chart a course for changing diabetes
Editors Note: High resolution images are available for free editorial use
For further details on the event: novonordisk.com/changingdiabetes
For further details on the UN Resolution: unitefordiabetes.org
Novo Nordisk is a healthcare company with an 80-year history of
innovation and achievement in diabetes care. In addition to diabetes care,
Novo Nordisk has a leading position within areas such as hemostasis
management, growth hormone therapy, and hormone therapy for women. Novo
Nordisk's business is driven by the Triple Bottom Line: a commitment to
economic success, environmental soundness, and social responsibility to
employees and customers. With headquarters in Denmark, Novo Nordisk employs
more than 23,600 employees in 79 countries, and markets its products in 179
countries. Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock Exchange
under the symbol 'NVO'. For global information, visit novonordisk.com; for
United States information, visit novonordisk-us.com.
For further information:
For further information: Media: Lori Moore, +1-609-919-7791; Investors:
Christian Qvist Frandsen, +1-609-919-7937, both Novo Nordisk Web Site: